Welcome

Company & Technology

BioAMPS International, LLC is an emerging life science company focused on the discovery, development and commercialization of proprietary antimicrobial peptide (AMPs) therapeutic solutions for the treatment of systemic infectious diseases, including methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-negative and gram-positive bacteria.

Our de novo rational design platform has produced a large portfolio of D-confirmation, alpha-helical antimocrobial peptides that are structurally manipulated to alter their hydrophobicity and amphipathicity properties. The charge substitutions and structure alterations on both the polar and non-polar faces of our peptides produce a unique “carpeted model” mechanism of action, broad spectrum of activity, and low level of toxicity to human cells. Our membrane-discriminate peptides are:

Membrane Targeted: we deploy positive charge substitutions on the non-polar face to facilitate cytoplasmic membrane selectivity.
Prokaryotic Specific: Our peptides are attracted to the unique lipid compositions and charge of prokaryotic membranes, focusing their activity specifically to bacteria, thereby reducing toxicity.
Half-life Prolonged: Unlike L-conformation forms, our D-conformation peptides are imperceptible to protease enzymes, providing extended circulating half lives.

Our Vision & Strategy

In parallel to our focused development of our lead compound, V13K, we will continue to aggressively mine our de novo structural design platform for additional D-conformation peptide analogs with specific and targeted activity against bacteria, fungi and viruses that may serve as follow on drug candidates for self-development or out-licensing. Of particular future interest is the unmet need for drug solutions to the problem of resistant Mycobacterium tuberculosis , a growing global epidemic that is generating approximately 500,000 new cases per year.

Our Team

bottom-rightOur core leadership team is led by David A. DeLong, President and CEO, a 25-year pharmaceutical industry veteran with commercial and general management experience in both small and large biopharma companies. Our Chief Scientific Officer is Robert Hodges, Ph.D., the scientific founder and the former President of the American Peptide Society. Our team is augmented by experienced microbiology, regulatory, pharmacology-toxicology, clinical development and product development advisors.

Comments are closed.